New drug combo shows promise for tough cancers
NCT ID NCT04798781
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of two drugs—telatinib (a pill that blocks tumor blood vessels) and Keytruda (an immunotherapy that helps the immune system attack cancer)—in 16 people with advanced stomach, gastroesophageal junction, or liver cancer. The goal was to see if the combo could slow cancer growth. The study is now complete, and results will show whether this approach is safe and effective enough to pursue in larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Telatinib (a targeted cancer pill) and Keytruda (an immunotherapy drug)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced stomach or liver cancer who have run out of standard therapies.
- What could go wrong
- This is a very small, early-phase trial with only 16 participants, so results may not apply to larger groups. The combination may cause significant side effects or fail to improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED STOMACH AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CS Cancer Beverly Hills
Beverly Hills, California, 90211, United States
-
CS Cancer at The Angeles Clinic and Research Institute
Los Angeles, California, 90025, United States
-
CS Cancer at the Samuel Oschin Cancer Center
Los Angeles, California, 90048, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication